• Dundee Corporation (DC.A) portfolio holding, TauRx Pharmaceuticals, has raised US$119 million to fund TauRx’s regulatory submissions in the UK, US and Canada
  • Proceeds will also be used to advance development plans for regulatory approval in China
  • President and CEO Jonathan Goodman sat down with Sabrina Cuthbert to discuss the news
  • Dundee Corporation is a Canadian independent holding company with a 3.2 per cent interest in TaxRx Pharmaceuticals
  • Dundee Corporation (DC.A) opened trading at C$1.37

Dundee Corporation (DC.A) portfolio holding, TauRx Pharmaceuticals, has raised US$119 million through a warrant exercise.

The proceeds will fund TauRx’s regulatory submissions in the UK, US and Canada and advance development plans for regulatory approval in China.

President and CEO Jonathan Goodman sat down with Sabrina Cuthbert to discuss the news. “We are extremely pleased to learn that TauRx was successful in its efforts to secure the necessary funding to undergo regulatory submissions of its promising Alzheimer’s treatment in 2023. We wish the company well in these efforts and look forward to its presentation of results of its LUCIDITY trial at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco on November 30th.”

TauRx announcement highlights:

  • TauRx achieved a substantial investment of US$119 million through the exercise of warrants received from the previously announced rights offering.
  • Proceeds will be used to fund regulatory submissions in the UK, US and Canada, and preparation for market availability
  • Shareholder commitment to TauRx represents a significant success story for UK-based life sciences research and development in areas of great unmet medical need
  • TauRx will present the Phase 3 findings at the Clinical Trials on Alzheimer’s Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco

Dundee holds 1,015,008 shares in TauRx, representing a 3.2 per cent interest in the company.

Dundee Corporation is a Canadian independent holding company. Through its operating subsidiaries, Dundee Corporation is an active investor focused on delivering long-term, sustainable value as a trusted partner in the mining sector with more than 30 years of experience making accretive mining investments.

Dundee Corporation (DC.A) opened trading at C$1.37.


More From The Market Online
labratory work

PharmaTher locks in FDA-assigned goal date of abbreviated NDA

PharmaTher Holdings (CSE:PHRM) locks in its U.S. FDA-assigned goal date of abbreviated new drug application for Oct. 29, 2024.

Sun Life misses core profit estimates for first time in 12 quarters

Sun Life (TSX:SLF) faces a setback as it reports its Q1 2024 results, missing core profit estimates for the first time in 12 quarters.

Optimi Health makes first international MDMA shipment

Optimi Health (CSE:OPTI) makes its first international shipment of MDMA to The Institute for Psychedelic Research at Tel Aviv University.

Oncolytics Biotech approved to expand pancreatic cancer program

Oncolytics Biotech (TSX:ONC), a cancer immunotherapy stock, receives ethics and German regulatory approvals for a new pancreatic cancer study.